TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.